Study of CT071 Injection in RRMM or PPCL

NCT ID: NCT05838131

Last Updated: 2025-01-07

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-28
• Study Completion Date: 2025-07-31

Brief Summary

A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

Detailed Description

This trial is a single-arm, open-label, dose-finding, first-in-human clinical trial. The main aim of this study is to preliminarily evaluate the safety and tolerability of CT071 after infusion, and explore the dose range of CT071 in patients with relapsed/refractory multiple myeloma or primary plasma cell leukemia, so as to determine the possible recommended therapeutic dose (RD).

Conditions

Multiple Myeloma; Primary Plasma Cell Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CAR-T cells Infusion

Biological: CART cells chimeric antigen receptor T cells

Group Type: EXPERIMENTAL

Experimental: CAR-T cells Infusion

Intervention Type: DRUG

Biological:

chimeric antigen receptor T cells

Interventions

Experimental: CAR-T cells Infusion

Biological:

chimeric antigen receptor T cells

Intervention Type: DRUG

Other Intervention Names

Single Group Assignment

Eligibility Criteria

Inclusion Criteria

1. Volunteer to participate in the clinical trial; fully understand and are informed of this trial and sign the informed consent form; Willing to follow and able to complete all trial procedures;

2. Age ≥ 18 years, male or female;

3. Patients with multiple myeloma who have received at least three lines therapy for multiple myeloma (requires relapse, progression, non-response after treatment with at least 1 proteasome inhibitor and at least 1 immunomodulator.

4. Patients with primary plasma cell leukemia progressed after treatment with at least 1 regimen;

5. Progressive disease at the time of enrollment according to the IMWG consensus for myeloma or plasma cell leukemia;

6. Have any of the following evaluable conditions:

1. Serum M-protein ≥ 5 g/L;

2. 24-hour urine M-protein ≥ 200 mg;

3. Abnormal serum free light chain (sFLC) ratio and affected FLC ≥ 100 mg/L in subjects with multiple myeloma who did not meet evaluable criteria for either serum or urine M-protein levels;

4. Circulating plasma cells ≥ 5% (PCL subjects only);

7. Estimated survival > 12 weeks;

8. Eastern Cooperative Oncology Group (ECOG) score 0-2;

9. Subjects had adequate organ function.

10. Female subjects of childbearing potential must have a negative serum pregnancy test at screening, be willing to use a highly effective and reliable method of contraception within 1 year after receiving the trial treatment, and absolutely prohibit egg donation during the trial and within 1 year after receiving the trial treatment;

11. Male subjects, if sexually active with a female of childbearing potential, are willing to use a highly effective and reliable method of contraception for 1 year after receiving trial treatment. All male subjects are absolutely prohibited from donating sperm during the trial and for 1 year after receiving the trial treatment.

Exclusion Criteria

1. Pregnant or lactating females;

2. Patients with a history of neurological disease, such as epilepsy, intracranial hemorrhage, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, memory impairment, spinal cord compression, psychiatric disease or any disease involving the central nervous system, or suspected central nervous system (CNS) metastasis;

3. Patients with other incurable malignant tumors within 5 years or at the same time, except for those with very low degree of malignancy;

4. Patients with active autoimmune diseases, including but not limited to psoriasis, rheumatoid arthritis, inflammatory bowel disease and other patients requiring long-term immunosuppressive therapy;

5. Received allogeneic stem cell transplantation within two years prior to screening;

6. Received autologous stem cell transplantation within 12 weeks prior to screening, or plan to receive autologous stem cell transplantation during the trial;

7. Any uncontrolled disease or disorder with important clinical significance investigator considered not applicable for the study;

8. Patients who had any uncontrolled active infection (defined as the presence of persistent signs or symptoms associated with infection that did not improve despite appropriate antiinfective treatment) or who required intravenous antiinfective agents (except for prophylactic treatment) within 4 weeks before apheresis. If there is clinical indications, investigators should consider screening EBV, CMV, and other related pathogenic microorganisms;

9. Major surgery within 2 weeks prior to screening, or planning to undergo major surgery within 4 weeks after trial treatment (excluding cataract and other surgery under local anesthesia);

10. Received treatment for the disease under study within 2 weeks prior to apheresis(or within five half-lives of the drug, whichever is shorter), including but not limited to cytotoxic therapy, proteasome inhibitors, immunomodulators, targeted therapy, radiotherapy, epigenetic therapy, etc.; Received anti-PD-1/PD-L1 monoclonal antibody or other investigational drug/invasive medical device within 4 weeksprior to apheresis;

11. Vaccination with live attenuated vaccine or mRNA vaccine within 8 weeks and inactivated vaccine within 4 weeks before screening;

12. Patients who are allergic or intolerant to CLD drugs, tocilizumab, or allergic to the ingredients of CT071 cell infusion preparation (DMSO); Or previous history of other severe allergies, such as anaphylactic shock;

13. Positive test results for any of the following: human immunodeficiency virus (HIV) antibody, Treponema pallidum antibody, hepatitis C virus (HCV) RNA, hepatitis B virus (HBV) surface antigen (HBsAg), HBV DNA;

14. The toxicities caused by the previous treatment have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) ≤ Grade 1, except for alopecia and other tolerable events as judged by the investigator;

15. Left ventricular ejection fraction (LVEF) < 50%;

16. Oxygen saturation < 92% at room air;

17. Received glucocorticoids within 7 days prior to apheresis, with the exception of inhaled glucocorticoids and physiologic replacement doses;

18. Other conditions considered inappropriate for participation in this clinical trial by the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CARsgen Therapeutics Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Shanghai Changzheng Hospital

OTHER

Sponsor Role: lead

Responsible Party

Juan Du

Chief physician, professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Juan Du

Role: PRINCIPAL_INVESTIGATOR

Shanghai Changzheng Hospital

Locations

Shanghai Changzheng Hospital

Shanghai, , China

Countries

China

References

Jin L, Gu S, Ruan Q, Lu J, Qiang W, He H, Fan X, Liu J, Guo P, Meng X, Rajakumaraswamy N, Chen D, Li Z, Du J. GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2025 Oct;12(10):e798-e807. doi: 10.1016/S2352-3026(25)00176-0.

Reference Type: DERIVED

PMID: 41062204 (View on PubMed)

Other Identifiers

CT071-CG7001

Identifier Type: -

Identifier Source: org_study_id